The Benefit of Hemodialysis Plus Hemoperfusion on Mortality

Summary

This multi-center, open-label, randomized controlled trial aims to investigate the efficacy of hemoperfusion (HP) combined with hemodialysis (HD) by evaluating all-cause mortality and cardiovascular mortality in maintenance hemodialysis patients.

Conditions

• End-stage Renal Disease

Interventions

DEVICE

hemoperfusion combined with hemodialysis

Hemoperfusion combined with hemodialysis treatment will perform at least once every two week. The hemoperfusion apparatus will use type HA130 resin hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)

DEVICE

hemodialysis

Blood purification (including low-flux hemodialysis, high-flux hemodialysis, or hemodiafiltration) treatment ≥10 hours per week

Sponsors & Collaborators

• Shanghai Zhongshan Hospital

  collaborator OTHER

• RenJi Hospital

  collaborator OTHER

• Ruijin Hospital

  collaborator OTHER

• Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

  collaborator OTHER

• Shanghai 6th People's Hospital

  collaborator OTHER

• Changhai Hospital

  collaborator OTHER

• Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

  collaborator OTHER

• Shanghai University of Traditional Chinese Medicine

  collaborator OTHER

• Shanghai Tongji Hospital, Tongji University School of Medicine

  collaborator OTHER

• Yangpu District Central Hospital Affiliated to Tongji University

  collaborator OTHER

• Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

  lead OTHER

Principal Investigators

• Gengru Jiang, doctoral · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-12-01

Primary Completion

2021-12-31

Completion

2021-12-31

Countries

• China

Study Locations